On June 10, 2020 Adagene Incorporated, a precision antibody engineering, discovery and development company, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), reported that the companies have entered into a strategic collaboration under which TRL will use Adagene’s SAFEbody technology platform to generate a masked antibody in combination with the cytotoxic payload technologies used at TRL, for the development of an ADC against a solid tumor target (Press release, Adagene, JUN 10, 2020, View Source [SID1234560985]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Adagene has developed the SAFEbody technology platform for discovery of a masked antibody which is activated by factors present in tumor tissues but not in healthy tissues. This allows for the tumor-specific targeting of antibodies with minimized on-target toxicity in healthy tissues. The tumor-specific targeting technology is expected to safely enhance the therapeutic index of the ADC delivery of the cytotoxic payload.
"We look forward to combining our SAFEbody technology with TRL’s ADC technologies to develop a treatment for a solid tumor target," said Peter Luo, Chief Executive Officer and Co-Founder of Adagene. "Adagene’s precision protein engineering capabilities enable us to create highly masked antibodies while retaining their efficacy. Traditional ADC technologies are limited in most solid tumor targets because toxicity was observed at optimal efficacious doses. Our new modality, POWERbody, combining SAFEbody with ADCs, aims to deliver safe and potent therapies toward a wide range of targets."
Financial terms and target identification were not disclosed.